Nivolumab-induced myocardial necrosis in a patient with lung cancer: A case report

Respir Med Case Rep. 2019 Apr 15:27:100839. doi: 10.1016/j.rmcr.2019.100839. eCollection 2019.

Abstract

A 74-year-old man with lung adenocarcinoma recurrence was admitted to our hospital because of dyspnea 7 days after receiving initial immunotherapy with nivolumab. Electrocardiography revealed ST-segment elevation in V1-6 and echocardiography showed a markedly reduced left ventricular ejection fraction of 9% and akinesis of the anteroseptal wall and apex. He died from acute heart failure 3 days after admission. Microscopically, multiple small foci of myocardial necrosis with few inflammatory cells were scattered in both ventricles. Obstruction of the coronary artery was not identified. We believed that the cause of death was acute heart failure possibly due to nivolumab-induced myocardial necrosis.

Keywords: Cardiotoxicity; Immune-related adverse events; LVEF, Left ventricular ejection fraction; Nivolumab; PD-1, Programmed death-1; PD-L1, Programmed death-ligand 1; irAE, Immune-related adverse event.

Publication types

  • Case Reports